Products independently developed by Wuhan Hull Medical Technology Development Co., Ltd.

SPICM-DNA automatic cell tumor screening and analysis system can automatically scan every exfoliated cell and accurately measure the DNA content of each cell. Based on the huge database of cervical exfoliated cells, advanced support vector machine and artificial intelligence neural network were used to identify diseased epithelial cells from a large number of detected cells, and 125 cell morphology and texture parameters were optimized. This instrument is very suitable for early diagnosis of cervical cancer. It integrates filming, automatic film loading, automatic film reading, automatic pathological analysis and automatic generation of graphic test reports. Give full play to the advantages of simple and easy exfoliated cell examination, no damage and easy acceptance by patients, overcome the shortcomings of poor smear quality, few observable cells and low positive diagnosis rate, and avoid missed diagnosis of patients with early cervical cancer. Compared with routine cytological examination, its sensitivity is obviously improved, human error is avoided, early cervical cancer cells can be found in time, and patients can be treated in time, which is incomparable to conventional cytological methods.

The system can be used for the diagnosis of cervical cancer and precancerous lesions, the evaluation of the malignant degree of cervical cancer and the prediction of the prognosis of cervical cancer. Our company's "SPICM-DNA Automatic Cell Tumor Screening and Analysis System" is an internationally advanced early detection system for cervical cancer. This product was introduced by Dr. Liu from the United States into the world advanced technology of American depth spectroscopy and imaging analysis. After five years' research, we have developed a new generation of products with independent intellectual property rights in combination with Wuhan University Scientific Instrument Engineering Technology Center, Hubei Spectrum and Imaging Technology Research Center, tongji hospital and Shandong Family Planning Commission. At the same time, the system embodies the valuable experience of more than 0/00 authoritative experts in gynecology and pathology in China. 200 1 this technology has been funded by the tenth five-year major scientific and technological research project, and the state supports 4 million yuan as research and development funds. At the end of 2003, it was successfully developed and accepted by experts organized by the Ministry of Science and Technology, and was awarded the invention patent certificate issued by China National Intellectual Property Administration (ZL2003101665438). In 2004, the clinical application in tongji hospital was 13 1 case, and the coincidence rate with manual examination reached 100%. In 2005, 8900 clinical trials were carried out in Shandong, and 23 cases were found missing manually.